CDK4 and breast cancer: Recently, the DAWNA-2 study, a Chinese multicenter phase 3 trial, reported that Dalpiciclib (a CDK4/6 inhibitor) significantly improved PFS in patients with HR+/HER2- advanced breast cancer compared to placebo when combined with letrozole or anastrozole as first-line therapy (mPFS 30.6 m vs. 18.2 m, HR = 0.51, p < 0.0001) [34].